1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

Xultophy Expands Label In Europe As First US Approval Decision Looms

 
• By Lucie Ellis-Taitt

Novo Nordisk has secured a European label extension for its dual type 2 diabetes therapy Xultophy for use in patients with moderate renal impairment – the EU nod is a another boost of confidence the Danish firm needs as it awaits a US regulatory decision.

The European Commission has approved the use of Novo Nordisk AS' Xultophy, a first-to-market once-daily combination of long-acting basal insulin Tresiba and glucagon-like peptide-1 receptor agonist Victoza in one pen, for use in type 2 diabetes patients with moderate renal impairment.

Xultophy's new drug application for use in type 2 diabetes patients is still pending at the US FDA, with a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

Biomea Plans To Advance Menin Inhibitor In Two Type 2 Diabetes Subgroups

 
• By Joseph Haas

With 52-week Phase II data, struggling Biomea said it would go forward in insulin-deficient type 2 diabetes patients and those who had not achieved HbA1c goals on GLP-1 therapy.

Metsera’s Phase IIb GLP-1 Data Show Competitive Efficacy, Tolerability

 
• By Joseph Haas

A week after Pfizer bid $4.9bn to acquire Metsera, the biotech reported mid-stage data showing 28-week efficacy comparable to tirzepatide and a “placebo-like” rate of diarrhea.

Acadia Gives Up In PWS After Another ACP-101 Phase III Miss

 
• By Joseph Haas

Acquired after an FDA advisory panel rejection in 2021, the oxytocin analog nasal spray was being positioned as a second drug to market for the rare disease Prader-Willi syndrome.

Roche Highlights Pipeline Transformed By Deals And ‘Raising The Bar’

 
• By Andrew McConaghie

The Swiss company believes new rigor in its internal decision-making and focus on best-in-class efficacy will deliver strong growth to 2030 and beyond.

More from Therapy Areas

Biomea Plans To Advance Menin Inhibitor In Two Type 2 Diabetes Subgroups

 
• By Joseph Haas

With 52-week Phase II data, struggling Biomea said it would go forward in insulin-deficient type 2 diabetes patients and those who had not achieved HbA1c goals on GLP-1 therapy.

Boehringer’s Jascayd Approval Brings New Mechanism To IPF

 
• By Jessica Merrill

The PDE4B inhibitor brings a new mechanism of action to the challenging respiratory disease and is the first drug approved for the indication in more than a decade.

Valneva Secures $500m Financing Ahead Of Lyme Disease Vaccine Readout

 
• By Kevin Grogan

The France-based firm shrugs off the disappointment of the FDA's suspension of Ixchiq.